Core Viewpoint - The article emphasizes the importance of selecting the right sectors in the A-share market, particularly focusing on emerging industries supported by government policies, such as integrated circuits, new energy, and biomedicine, which are expected to yield significant returns in the coming year [1]. Group 1: Selection Logic - The ten selected stocks are based on three hard standards: policy support, performance certainty, and reasonable valuation [3]. - Policy support is derived from the Ministry of Industry and Information Technology's focus on emerging pillar industries, which will benefit from research subsidies and industrial support [3]. - Performance is guaranteed with expected revenue/net profit growth of at least 20% and a return on equity (ROE) of at least 15% by 2025, with data sourced from company annual reports [3]. - Valuation is considered reasonable if the price-to-earnings (PE) and price-to-book (PB) ratios are below industry averages or at historical lows, providing a safety margin [3]. Group 2: Potential Stocks Analysis - The ten companies span key sectors such as semiconductors, new energy, and biomedicine, each with solid growth logic supported by authoritative data [5]. - Notable companies include: - Northern Huachuang (002371): A leader in semiconductor equipment with a leading domestic market share and a PEG of 1.2 [5]. - China Great Wall (000066): A core player in the Xinchuang hardware sector with a historical low PE of approximately 28 times and strong asset integration expectations [5]. - Desheng Technology (002908): A small-cap stock benefiting from social security services and data rights, with high elasticity expected as policies accelerate in 2026 [5]. Group 3: Core Sector Opportunities - Three key sectors are highlighted for their concentrated policy benefits and strong growth certainty: - Semiconductors and domestic substitution: The Ministry of Industry and Information Technology is promoting industrial foundation reconstruction, benefiting companies like SMIC and Northern Huachuang [6]. - New energy (photovoltaics and energy storage): The national energy work conference aims for an additional 200 million kilowatts of wind and solar installations by 2026, with companies like Longi Green Energy and CATL positioned to benefit [6]. - Biomedicine and innovative drugs: As an emerging pillar industry, stable policies and accelerated overseas expansion are expected to benefit companies like Heng Rui Medicine and Huahai Pharmaceutical [6]. Group 4: Practical Guide for Investors - Investors are advised to utilize three practical methods to seize opportunities without falling into pitfalls: - Verify authoritative information by checking company annual reports on the Shanghai and Shenzhen Stock Exchanges to confirm performance and order status [8]. - Diversify investments by selecting 1-2 stocks from each of the semiconductor, new energy, and biomedicine sectors to mitigate risks [8].

Group 1: Overall Industry Outlook - In 2026, the pharmaceutical industry is expected to experience a surge in innovative drugs, a recovery in the CXO sector, transformation in traditional Chinese medicine, contraction of retail pharmacies, restructuring of hospitals, and a wave of mergers and acquisitions, leading to increased industry differentiation and stronger players remaining dominant [1] Group 2: Innovative Drugs - A total of 76 innovative drugs were approved in 2025, marking a 58% increase from the previous year, with over 150 licensing transactions totaling more than $130 billion, indicating robust growth in China's innovative drug sector [3] - Approximately 20 major innovative drugs are anticipated to be approved in China in 2026, covering various therapeutic areas including oncology and rare diseases, with notable examples such as BL-B01D1 for esophageal squamous carcinoma [3][4] Group 3: CXO Sector - The CXO (Contract Research Organization) industry is experiencing a recovery driven by external factors such as U.S. interest rate cuts and increased R&D investments from multinational pharmaceutical companies, alongside domestic demand for CRO services [5][6] - The penetration rate of outsourcing in areas like ADCs and oligonucleotides is expected to rise to 65%, with companies like WuXi AppTec and Kelun Biotech showing strong growth in these segments [6] Group 4: Traditional Chinese Medicine - The Chinese medicine sector is entering an era of refined management, driven by policy upgrades and market innovations, with a focus on quality and cost balance in procurement [7][9] - By the end of 2026, China aims to establish 180 domestic and 30 international standards for traditional Chinese medicine, with the market expected to exceed 1 trillion yuan for the first time in 2024 [9] Group 5: Medical Devices - The medical device industry is shifting from price suppression to innovation-driven growth, with domestic companies rapidly advancing in high-end imaging, surgical robots, and AI medical devices [10] - Chinese medical device companies are increasingly expanding into international markets, with a notable rise in export volumes expected by 2026 [10] Group 6: Retail Pharmacies - The offline pharmacy sector is projected to contract significantly due to the growth of O2O and B2C models, with over 15,975 stores closing by September 2025, reflecting a 73% year-on-year increase in closures [12][13] Group 7: Private Hospitals - Private hospitals are facing severe challenges, with an average of 1.4 closures per day in 2024, and this trend is expected to continue into 2026 due to regulatory pressures and financial difficulties [14][15]

Market Overview - A-shares opened high and experienced fluctuations, with the Shanghai Composite Index closing at 4085.77 points, up 0.05% [1] - The Shenzhen Component Index rose 0.06% to 14030.56 points, while the CSI 300 Index fell 0.29% to 4776.67 points [1] - The total trading volume in the two markets reached 2.85 trillion yuan, marking the second consecutive day above 2.8 trillion yuan [1] Sector Performance - The semiconductor sector saw significant gains, driven by rising prices of storage chips, with stocks like Tongcheng New Materials and Hengkun New Materials hitting the daily limit [1][2] - The controlled nuclear fusion concept gained traction, with stocks such as Wangzi New Materials and China Nuclear Engineering hitting the daily limit, following breakthroughs in experimental methods [3] - The non-ferrous nickel sector also experienced a rally, with the main nickel contract reaching a high of $18,735 per ton, the highest since June 2024 [4] Institutional Insights - Goldman Sachs recommends overweight positions in A-shares and H-shares, projecting a 20% increase in the MSCI China Index and a 12% rise in the CSI 300 Index for 2026, driven by double-digit earnings growth and moderate valuations [5] - Huaxi Securities anticipates an early start to the spring market rally, maintaining a bullish outlook and suggesting focus on emerging growth sectors and anti-involution opportunities [6] - Shenwan Hongyuan emphasizes the ongoing structural themes in the spring market, highlighting opportunities in AI computing chains and cyclical stocks [8] Technical Analysis - Dongfang Securities notes that the Shanghai Composite Index is approaching the 4100-point mark, predicting a slowdown in upward momentum and potential volatility [9]

Core Viewpoint - The pharmaceutical and medical device sectors in China are expected to experience a convergence of industrial, policy, and capital cycles by 2026, presenting significant investment opportunities in innovative therapies and medical devices [1] Pharmaceutical Industry - The Chinese innovative drug sector is anticipated to reach a performance inflection point and valuation restructuring, with a focus on next-generation therapies such as ADCs, bispecific/multispecific antibodies, cell and gene therapies, and small nucleic acids [1] - Research and development spending by pharmaceutical companies is showing marginal improvement, with opportunities for domestic substitution and breakthroughs in mid-to-high-end products [1] Medical Device Industry - The impact of centralized procurement policies is gradually diminishing, while overseas markets continue to grow rapidly, suggesting a recovery in the performance of related companies [1] - Investment focus should be on rapidly scaling products post-procurement implementation and medical device companies driven by equipment upgrades [1] Blood Products Market - The demand for blood products and the volume of plasma collection are consistently increasing, with resources concentrating among leading companies in the sector [1] Investment Opportunities - The overall pharmaceutical industry is entering a critical phase of innovation realization and global expansion, with investment opportunities concentrated in innovative companies that possess global competitiveness [1] ETF Overview - The Guotai Innovation Pharmaceutical ETF (159377) tracks the Innovation Pharmaceutical Index (399275), which has a daily price fluctuation limit of 20%, focusing on companies with high R&D investment and innovation capabilities in the pharmaceutical sector [1]

Group 1 - The semiconductor equipment ETF (159516) surged over 7% on January 7, with a net inflow of over 2.8 billion yuan in the past 20 days, indicating market interest in domestic substitution logic [1] - Changxin Storage's IPO application has been accepted, positioning it as China's largest and most advanced integrated DRAM R&D, design, and manufacturing enterprise since its establishment in 2016 [1] - According to Omdia data, Changxin has become the largest DRAM manufacturer in China and the fourth globally based on production capacity and shipment volume [1] Group 2 - The IPO aims to raise 29.5 billion yuan, with 7.5 billion yuan allocated for upgrading existing wafer manufacturing lines, 13 billion yuan for DRAM technology upgrades, and 9 billion yuan for advanced technology research and development [1] - The financing from Changxin's IPO is expected to significantly enhance its capital expenditure certainty, accelerating the construction of storage production lines and increasing the domestic substitution rate, which is favorable for investments in related semiconductor equipment and testing sectors [1][2]

Core Viewpoint - The A-share market is experiencing an upward trend, particularly in the semiconductor sector, driven by rising prices and strong demand across various segments [1] Semiconductor Industry Summary - The semiconductor equipment, analog chips, and semiconductor materials sectors are all seeing price increases due to tight supply and demand dynamics [1] - The storage sector is on an upward cycle, with strong demand from cloud infrastructure and an opening for domestic production [1] - In the wafer foundry segment, BCD process prices are rising, and there is an increase in demand for analog chips alongside accelerated domestic substitution [1] - The validation of domestic photolithography machines is promoting the expansion of wafer fabs, reinforcing the logic of domestic material substitution [1] - AI computing power demand is continuously driving growth in the storage industry chain, with an upward cycle for analog chips and development opportunities in core chip areas like GPUs [1] - Several semiconductor companies are accelerating product iteration and commercialization, creating a complete product matrix from chips to solutions, with significant resonance between technological innovation and market demand [1] - The semiconductor probe card industry is characterized by high prosperity and dual drivers of domestic substitution, with a projected global market size of approximately 18.6 billion RMB in 2024, and a domestic market share of nearly 15% but a domestic substitution rate of less than 5%, indicating significant replacement potential [1] - High technical barriers exist in the industry, with leading companies gaining technological advantages through binding with IDM/foundry firms, while domestic semiconductor manufacturing capacity expansion provides development opportunities for local firms [1] Investment Opportunities - The Southern Semiconductor ETF (159325.SZ) and Southern Sci-Tech Chip ETF (588890.SH) cover the semiconductor industry chain, including storage, analog chips, wafer foundry, and equipment materials, benefiting from the upward industry cycle and accelerated domestic substitution, presenting long-term investment value [1]

Market Overview - The A-share market opened strongly, with the Shanghai Composite Index surging past 4070 points, marking a ten-year high and a record-breaking 13 consecutive bullish days [1] - The trading volume is expected to reach 2.7 trillion yuan, significantly higher than the previous month's low levels, indicating a substantial influx of capital [1][6] Sector Performance - Financial sectors, particularly insurance and securities, played a crucial role in driving the index higher, with state-backed funds actively participating [2][4] - Following the financial sector's lead, cyclical stocks, including tourism and metals, also experienced significant gains, reflecting rapid capital movement across industries [2] - Technology growth stocks showed strong performance, particularly in brain-computer interface concepts and semiconductor equipment, driven by domestic advancements and expected production increases [3] Capital Flow and Market Sentiment - The market has seen a remarkable increase in trading volume, with a notable rise in margin financing, indicating accelerated entry of leveraged and external funds [6] - The phenomenon of "deposit migration" suggests that household savings are shifting towards the stock market, enhancing liquidity [6] - Despite strong index performance, many individual stocks have not outperformed the index, leading to a situation where investors are "earning the index but not making money" [8][9] Economic and Regulatory Environment - The macroeconomic outlook for 2026 is optimistic, with expectations of stable GDP growth around 5% and easing trade tensions between the US and China [12] - Regulatory measures are tightening, with a focus on improving the quality of listed companies, which is expected to enhance the overall investment value of the A-share market [10][13] - The anticipated easing of monetary policy by the Federal Reserve could further attract global capital to emerging markets, including China [12] Structural Changes in the Market - The A-share market is transitioning from a focus on scale expansion to prioritizing quality, as evidenced by a decrease in IPO numbers and financing amounts [13] - The increasing representation of high-tech and strategic emerging industries within the A-share market supports the foundation for a structural bull market [13]

Group 1: Key Insights from Reports - The 2026 "Two Heavy" and "Two New" policies are accelerating deployment, with a potential increase in the issuance of ultra-long special government bonds [14] - The core viewpoint indicates that the "Two Heavy" policies will remain a key focus for stabilizing investment, while "Two New" policies will emphasize structural upgrades and support consumption [14] - The supply of ultra-long government bonds may rise, but the trend in interest rates is expected to remain stable due to low inflation and growth targets [14] Group 2: Industry Developments - The low-altitude economy industry is witnessing significant advancements, including the first successful cross-strait flight verification of a ton-level unmanned aerial vehicle and the first flight of a 6-ton tilt-rotor aircraft [14] - Shanghai has released measures to accelerate the construction of a low-altitude economy advanced manufacturing cluster in the Yangtze River Delta [14] - Companies like Qingyun Technology are collaborating to create a comprehensive cloud platform for the low-altitude economy, significantly improving route planning and approval efficiency [14] Group 3: Company News - Semiconductor company SMIC is planning to acquire SMIC North, which may accelerate domestic substitution and advanced process progress [14] - Tesla China has introduced a limited-time long-term car purchase plan, offering low-interest financing options for its Model 3 and Model Y vehicles [13] - AMD has unveiled several AI chips at the CES, highlighting the growing demand for computing power in AI applications [13]

今日（1月7日），A股光刻机概念股集体大涨。开盘仅1秒钟，国风新材就被大单直线拉升至涨停板。紧随其 后，华融化学、常青科技也直线拉升涨停。光刻机指数整体涨幅超过5%并创出新高，近20只相关个股涨停或 涨超10%。 半导体产业链，集体异动！ 盘中，半导体设备板块也大幅走高，芯源微20%涨停，安集科技、先锋精科、聚辰股份等纷纷大涨。有分析人 士指出，隔夜美股半导体板块大幅走高，在一定程度上带动了A股相关概念股。另外，半导体国产替代逻辑持 续强化，推动资金转向量价齐升的半导体产业链。 集体大涨 今日盘中，A股半导体产业链集体大涨。截至中午收盘，光刻机指数涨幅超过5%，半导体设备指数、半导体 材料指数涨幅超过4%，晶圆产业指数、半导体硅片指数涨超3%。 兴业证券近期发布的研报指出，国产半导体设备产业除遵循"技术周期"和"库存周期"驱动外，还受益于国产替 代需求，且不仅在于本身各类半导体设备工艺环节的国产替代，还在于需求端芯片设计企业的国产替代，在于 制造端逻辑、存储晶圆制造的国产替代。展望当下，AI驱动下先进工艺突破愈加紧迫，半导体设备产业已进 入新一轮成长周期。 银河证券认为，在外部环境背景下，供应链安全与自主可控 ...

Market Overview - The A-share market opened high on January 7, with the Shanghai Composite Index rising by 0.29% to 4095.54 points, the Shenzhen Component Index up by 0.35% to 14071.35 points, and the ChiNext Index increasing by 0.41% to 3332.74 points, marking a four-year high [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.84 trillion yuan, an increase of 53.8 billion yuan compared to the previous trading day [1] Sector Performance - The photolithography concept stocks surged, with Guofeng New Materials hitting the limit up for two consecutive days, and several other stocks like Nanda Optoelectronics and Tongcheng New Materials also reaching the limit up [1] - The controllable nuclear fusion concept showed strong performance, with stocks like Wangzi New Materials and China First Heavy Industries hitting the limit up [1] - The brain-computer interface concept continued its strong trend, with stocks such as Innovation Medical and Nanjing Panda achieving three consecutive limit ups [1] - Semiconductor equipment stocks were actively traded, with stocks like Chip Source Microelectronics and Hengkun New Materials hitting the limit up by 20% [1] - The electric grid equipment sector showed strength, with Sanbian Technology and China West Electric reaching the limit up [1] - In contrast, oil and gas stocks performed poorly, with China National Offshore Oil Corporation experiencing a decline [1] Hot Sectors - The storage chip concept was strong, with stocks like Yingxin Development achieving two consecutive limit ups, and others like Puran Shares and Jiangbolong also rising [2] - The nickel concept stocks saw a rally, with stocks like Greeenmei hitting the limit up, supported by a significant increase in nickel prices [3] - The controllable nuclear fusion concept stocks rose, with breakthroughs in experimental methods reported, indicating long-term growth potential for the industry [4] Institutional Insights - Huaxi Securities noted that the spring market rally has started early, maintaining a bullish outlook, and suggested focusing on emerging growth sectors and anti-involution opportunities [5] - Shenwan Hongyuan Securities emphasized that the spring market structure remains unchanged, with high elasticity in thematic opportunities, particularly in AI and cyclical sectors [5] - Dongfang Securities indicated that the Shanghai Composite Index is approaching the 4100-point mark, predicting a slowdown in upward momentum and potential volatility [6]